Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients

Subjects: ALK; ddPCR; mutation

  • Source: Li, W, Zwierenga, F, Andini, K D, Bucher, J M, Scherpen, F, Hiltermann, T J N, Groen, H J M, van der Wekken, A J, Kok, K & Berg, A V D 2025, 'Presence of On-Target Resistant Mutation in Pre-Treatment

تفاصيل العنوان

×
Academic Journal

Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib:A Nationwide Cohort Study in Patients With ALK-Positive NSCLC

Subjects: Alectinib; NSCLC; Pharmacokinetics

  • Source: Heersche, N, Lanser, D A C, Muntinghe-Wagenaar, M B, Mohmaed Ali, M I, Ulas, E B, Trooster, T M A, de Jonge, E, Oomen-de Hoop, E, Paats, M S, Bahce, I, Croes, S, Hendriks, L E L, van der Wekken, A J,

تفاصيل العنوان

×
Academic Journal

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Subjects: ALK; Circulating tumor DNA; Lorlatinib

  • Source: Soo, R A, Martini, J F, van der Wekken, A J, Teraoka, S, Ferrara, R, Shaw, A T, Shepard, D, Calella, A M, Polli, A, Toffalorio, F, Tomasini, P, Chiu, C H, Kowalski, D M, Kim, H R & Solomon, B J 2023,

تفاصيل العنوان

×
Academic Journal

Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer

Subjects: ALK degradation; CDK4/6 inhibition; Dual degradation

  • Source: Wang, S, Luo, D, Pu, C, Ma, X, Zhang, H, Feng, Z, Deng, R, Yu, S, Liu, Y, Huang, Q & Li, R 2023, 'Discovery of the GSH responsive “Y-PROTACs” targeting ALK and

تفاصيل العنوان

×
Academic Journal

Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer

Subjects: ALK degradation; CDK4/6 inhibition; Dual degradation

  • Source: Wang, S, Luo, D, Pu, C, Ma, X, Zhang, H, Feng, Z, Deng, R, Yu, S, Liu, Y, Huang, Q & Li, R 2023, 'Discovery of the GSH responsive “Y-PROTACs” targeting ALK and

تفاصيل العنوان

×
Academic Journal

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Subjects: ALK; Circulating tumor DNA; Lorlatinib

  • Source: Soo, R A, Martini, J F, van der Wekken, A J, Teraoka, S, Ferrara, R, Shaw, A T, Shepard, D, Calella, A M, Polli, A, Toffalorio, F, Tomasini, P, Chiu, C H, Kowalski, D M, Kim, H R & Solomon, B J 2023,

تفاصيل العنوان

×
Academic Journal

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer:Local Experience and Review of the Literature

Subjects: ALK; Non-small cell lung cancer; Mutation

  • Source: Koopman, B, Groen, H J M, Schuuring, E, Hiltermann, J, Timens, W, den Dunnen, W F A, van den Berg, A, ter Elst, A, van Kruchten, M, Kluiver, J, Hiddinga, B, Hijmering-Kappelle, L, Groves, M, Vilachá

تفاصيل العنوان

×
Academic Journal

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting:preliminary analysis in a Chinese cohort

Subjects: Alectinib; ALK fusion variants; ALK+ non-small cell lung cancer (NSCLC)

  • Source: Zou, Z, Gu, Y, Liang, L, Hao, X, Fan, C, Xin, T, Zhao, S, Liu, Z, Guo, Y, Ma, K, Li, H, Zhang, C, Shan, L, Zhang, Y, Dong, G, Peng, Y, Shen, F, Song, X, Christopoulos, P, van der Wekken, A J, Okuda,

تفاصيل العنوان

×
Academic Journal

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer:Local Experience and Review of the Literature

Subjects: ALK; Non-small cell lung cancer; Mutation

  • Source: Koopman, B, Groen, H J M, Schuuring, E, Hiltermann, J, Timens, W, den Dunnen, W F A, van den Berg, A, ter Elst, A, van Kruchten, M, Kluiver, J, Hiddinga, B, Hijmering-Kappelle, L, Groves, M, Vilachá

تفاصيل العنوان

×
Academic Journal

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting:preliminary analysis in a Chinese cohort

Subjects: Alectinib; ALK fusion variants; ALK+ non-small cell lung cancer (NSCLC)

  • Source: Zou, Z, Gu, Y, Liang, L, Hao, X, Fan, C, Xin, T, Zhao, S, Liu, Z, Guo, Y, Ma, K, Li, H, Zhang, C, Shan, L, Zhang, Y, Dong, G, Peng, Y, Shen, F, Song, X, Christopoulos, P, van der Wekken, A J, Okuda,

تفاصيل العنوان

×